Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(2):86-87; doi:10.1093/jnci/97.2.86
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Travis, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Travis, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Anastrozole Data Show Continued Delay in Relapse, But No Clear Survival Advantage

Kate Travis

The first 10% of the full text of this article appears below.

For the first time in 20 years, another class of drugs—aromatase inhibitors—is challenging tamoxifen as the treatment of choice for postmenopausal women with early breast cancer. However, the higher cost of at least one of the aromatase inhibitors and the lack of a statistically significant advantage in breast cancer survival give some researchers pause in wholeheartedly endorsing the drugs.

Final results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, presented at this year's San Antonio Breast Cancer Symposium and published simultaneously in The Lancet, found that, compared with tamoxifen, anastrozole (Arimidex) improved disease-free survival by 13% (17% among hormone-responsive . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?